Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Large Decline in Short Interest

by · The Cerbat Gem

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Get Free Report) saw a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 9,927 shares, a drop of 85.3% from the June 30th total of 67,330 shares. Based on an average trading volume of 18,424 shares, the short-interest ratio is currently 0.5 days. Approximately 0.5% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up approximately 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th largest position. Sabby Management LLC owned about 28.04% of Biodexa Pharmaceuticals as of its most recent SEC filing. Institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Trading Down 1.8%

NASDAQ BDRX traded down $0.03 during mid-day trading on Friday, hitting $1.65. The company’s stock had a trading volume of 63,546 shares, compared to its average volume of 412,269. The stock’s fifty day simple moving average is $2.84 and its two-hundred day simple moving average is $4.82. Biodexa Pharmaceuticals has a 52-week low of $1.64 and a 52-week high of $59.40.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on BDRX shares. Weiss Ratings raised Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. Wall Street Zen cut Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Get Our Latest Stock Analysis on Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Company Profile

(Get Free Report)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.

See Also